ImmunityBio's recently approved cancer drug has plenty of momentum. However, valuation concerns and clinical and regulatory ...

ImmunityBio recently reported full-year 2025 results showing revenue rising to US$113.29 million while net loss narrowed to US$351.4 million, driven largely by the commercial rollout of ANKTIVA and ...

Why ImmunityBio’s latest bladder cancer trial update matters for the stock ImmunityBio (IBRX) has attracted fresh attention after reporting that its Phase 2 QUILT 2.005 trial in BCG naïve non muscle ...

ImmunityBio announced this morning that it had reached a major enrollment threshold for one of its clinical trials. It also highlighted initial success in treating patients with Non-Hodgkin lymphoma ...

Financial giants have made a conspicuous bullish move on ImmunityBio. Our analysis of options history for ImmunityBio (NASDAQ:IBRX) revealed 19 unusual trades. Delving into the details, we found 57% ...

The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved ...

The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved ...

This approval marks a significant milestone as it expands the treatment’s availability to 33 countries, enhancing ImmunityBio’s global commercial presence. ANKTIVA in combination with BCG is now the ...

The MarketWatch News Department was not involved in the creation of this content. -- ImmunityBio partner Accord Healthcare to deploy an 85-person sales force to drive ANKTIVA commercialization across ...

Durable complete responses with CAR-NK + Rituximab in patients who failed current standards of care in Waldenstrom’s Non-Hodgkins lymphoma (NHL). Long-term evaluable patients demonstrate ongoing ...

Pharmaceutical drugs developed by two local companies received approvals in the European Union last month. On Dec. 12, Culver City-based ImmunityBio Inc. announced that the European Medicines Agency, ...

Shares of cancer and infectious disease therapy developer ImmunityBio, Inc. (NASDAQ: IBRX), spiked 34% higher as of 1 p.m. ET on Friday and are now up a staggering 127% this week after an incredible ...